BRCA1 breast cancer risk is modified by CYP19 Polymorphisms in Ashkenazi Jews

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 5, 2009, Pages 1617-1623

  Raskin, Leon ^a   Lejbkowicz, Flavio ^a   Barnett Griness, Ofra ^a   Dishon, Sara ^a   Almog, Ronit ^a   Rennert, Gad ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; ESTROGEN RECEPTOR; VALINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; CYP19 GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC RISK; HAPLOTYPE; HUMAN; JEW; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; ALLELES; AROMATASE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENES, BRCA2; GENOTYPE; HAPLOTYPES; HUMANS; ISRAEL; JEWS; LOGISTIC MODELS; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 66549117869     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0060     Document Type: Article

References (52)

1. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004;6:229-239 (Pubitemid 39440251)
2. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004;4:665-676
3. Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996;2:1179-1183 (Pubitemid 26375392)
4. Abeliovich D, Kaduri L, Lerer I, et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997;60:505-514 (Pubitemid 27097598)
5. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357:115-123 (Pubitemid 47057729)
6. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-271
7. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408 (Pubitemid 27208598)
8. Hopper JL, Southey MC, Dite GS, et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741-747 (Pubitemid 29445010)
9. Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998;352:1337-1339 (Pubitemid 28510913)
10. Ballard-Barbash R, Klabunde C, Paci E, et al. Breast cancer screening in 21 countries: delivery of services, notification of results and outcomes ascertainment. Eur J Cancer Prev 1999;8:417-426 (Pubitemid 30048071)
11. Offit K. BRCA mutation frequency and penetrance: new data, old debate. J Natl Cancer Inst 2006;98:1675-1677 (Pubitemid 44942706)
12. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-1706 (Pubitemid 44942707)
13. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002;360:187-195 (Pubitemid 34804645)
14. Jakubowska A, Narod SA, Goldgar DE, et al. Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland. Cancer Epidemiol Biomarkers Prev 2003;12:457-459 (Pubitemid 36578485)
15. Kadouri L, Easton DF, Edwards S, et al. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer 2001;85:36-40. (Pubitemid 32695713)
16. Kadouri L, Kote-Jarai Z, Easton DF, et al. Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Int J Cancer 2004;108:399-403. (Pubitemid 37549605)
17. Levy-Lahad E, Lahad A, Eisenberg S, et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A 2001;98:3232-3236 (Pubitemid 32220828)
18. Rebbeck TR, Kantoff PW, Krithivas K, et al. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet 1999;64:1371-1377 (Pubitemid 30468755)
19. Rebbeck TR, Wang Y, Kantoff PW, et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 2001;61:5420-5424 (Pubitemid 32694921)
20. Redston M, Nathanson KL, Yuan ZQ, et al. The APCI1307K allele and breast cancer risk. Nat Genet 1998;20:13-14 (Pubitemid 28410335)
21. Wang WW, Spurdle AB, Kolachana P, et al. A single nucleotide polymorphism in the 5′ untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2001;10:955-960 (Pubitemid 32844903)
22. Antoniou AC, Sinilnikova OM, Simard J, et al. RAD51 135G->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007;81:1186-1200 (Pubitemid 350211449)
23. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-285
24. Hsieh CC, Trichopoulos D, Katsouyanni K, Yuasa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer 1990;46:796-800.
25. Polymeropoulos MH, Xiao H, Rath DS, Merril CR. Tetranucleotide repeat polymorphism at the human aromatase cytochrome P-450 gene (CYP19). Nucleic Acids Res 1991;19:195.
26. Baxter SW, Choong DY, Eccles DM, Campbell IG. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001;22:347-349 (Pubitemid 32175526)
27. Haiman CA, Hankinson SE, Spiegelman D, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000;87:204-210 (Pubitemid 30434346)
28. Healey CS, Dunning AM, Durocher F, et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 2000;21:189-193 (Pubitemid 30098702)
29. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresen-Dale AL. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998;8:43-48 (Pubitemid 28097600)
30. Probst-Hensch NM, Ingles SA, Diep AT, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer 1999;6:165-173 (Pubitemid 29260048)
31. Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 1999;79:456-463 (Pubitemid 29046219)
32. Miyoshi Y, Ando A, Hasegawa S, et al. Association of genetic polymorphisms in CYP19 and CYP1A1 with the oestrogen receptor-positive breast cancer risk. Eur J Cancer 2003;39:2531-2537 (Pubitemid 37340166)
33. Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer 2000;89:325-328 (Pubitemid 30620284)
34. Ahsan H, Whittemore AS, Chen Y, et al. Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study. Breast Cancer Res 2005;7:R71-81.
35. Tworoger SS, Chubak J, Aiello EJ, et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:94-101. (Pubitemid 38116626)
36. Dunning AM, Dowsett M, Healey CS, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-945 (Pubitemid 38868140)
37. Paynter RA, Hankinson SE, Colditz GA, Kraft P, Hunter DJ, De Vivo I. CYP19 (aromatase) haplotypes and endometrial cancer risk. Int J Cancer 2005;116:267-274 (Pubitemid 40967264)
38. Gennari L, Masi L, Merlotti D, et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 2004;89:2803-2810 (Pubitemid 38766369)
39. Haiman CA, Dossus L, Setiawan VW, et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 2007;67:1893-1897 (Pubitemid 46424203)
40. Riancho JA, Valero C, Naranjo A, Morales DJ, Sanudo C, Zarrabeitia MT. Identification of an aromatase haplotype that is associated with gene expression and postmenopausal osteoporosis. J Clin Endocrinol Metab 2007;92:660-665 (Pubitemid 46255311)
41. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-2318 (Pubitemid 34441658)
42. Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029-2034 (Pubitemid 38375563)
43. Hirose K, Matsuo K, Toyama T, Iwata H, Hamajima N, Tajima K. The CYP19 gene codon 39 Trp/Arg polymorphism increases breast cancer risk in subsets of premenopausal Japanese. Cancer Epidemiol Biomarkers Prev 2004;13:1407-1411 (Pubitemid 39071569)
44. Haiman CA, Stram DO, Pike MC, et al. A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 2003;12:2679-2692 (Pubitemid 37304690)
45. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-434 (Pubitemid 34112296)
46. Thompson D, Easton D. The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 2004;9:221-236 (Pubitemid 39545740)
47. Ralph DA, Zhao LP, Aston CE, et al. Age-specific association of steroid hormone pathway gene polymorphisms with breast cancer risk. Cancer 2007;109:1940-1948 (Pubitemid 46744186)
48. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000;356:1876-1881
49. Clarke RB, Howell A, Anderson E. Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Res Treat 1997;45:121-133 (Pubitemid 27399960)
50. Zeps N, Bentel JM, Papadimitriou JM, D'Antuono MF, Dawkins HJ. Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth. Differentiation 1998;62:221-226 (Pubitemid 28165705)
51. Furuta S, Jiang X, Gu B, Cheng E, Chen PL, Lee WH. Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proc Natl Acad Sci U S A 2005;102:9176-9181 (Pubitemid 40923537)
52. Rudland PS, Fernig DG, Smith JA.Growth factors and their receptors in neoplastic mammary glands. Biomed Pharmacother 1995;49:389-399